Medical dermatology company LEO Pharma A/S reported on Tuesday the completion of the acquisition of the exclusive rights to develop and market brodalumab (marketed as Kyntheum in the EU) for the treatment of moderate-to-severe psoriasis outside of Europe through a new sub-licencing agreement with Bausch Health Ireland Limited.

The new sub-licensing agreement includes Australia, Brazil, Egypt, Mexico, Russia and Saudi Arabia. This agreement complements the ongoing licensing agreement between the two companies to develop and market brodalumab for moderate-to-severe psoriasis in Europe.

Pursuant to the new arrangement, Bausch Health has awarded LEO Pharma A/S with an exclusive license to its global rights to brodalumab, but continues to hold the rights for the US and Canada.

Outside of the EU, Bausch Health Companies Inc and AstraZeneca have owned the global commercial rights for brodalumab except in Japan and other Asian countries, where the rights are owned by Kyowa Kirin Co Ltd.

Psoriasis is a common, chronic, immune-mediated, inflammatory disease that primarily involves the skin. Psoriasis can be a painful, disabling and stigmatising condition with substantial social and psychological impact on a person's life.